118 related articles for article (PubMed ID: 21077727)
1. Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritis.
Roos JC; René C; Ostor AJ
Cutan Ocul Toxicol; 2011 Jun; 30(2):160-2. PubMed ID: 21077727
[TBL] [Abstract][Full Text] [Related]
2. More on periorbital infections following therapy with biological agents.
Lazzeri D; Agostini T; Figus M; Nardi M; Pantaloni M; Lazzeri S
Cutan Ocul Toxicol; 2011 Dec; 30(4):335-6. PubMed ID: 21639704
[No Abstract] [Full Text] [Related]
3. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
4. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
5. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
6. Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge.
Kucharekova M; Winnepenninckx V; Frank J; Poblete-Gutiérrez P
Int J Dermatol; 2008 Nov; 47 Suppl 1():25-8. PubMed ID: 18986481
[TBL] [Abstract][Full Text] [Related]
7. [Cutaneous infection due to Mycobacterium chelonae during anti-TNF therapy].
Adenis-Lamarre E; Kostrzewa E; Texier-Maugein J; Doutre MS
Ann Dermatol Venereol; 2009 Nov; 136(11):811-4. PubMed ID: 19917435
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
9. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
10. Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab.
van de Sande MG; van Slobbe-Bijlsma ER
Rheumatology (Oxford); 2012 Mar; 51(3):577-8. PubMed ID: 22096010
[No Abstract] [Full Text] [Related]
11. [Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis].
Fournier A; Nony A; Rifard K
Nephrol Ther; 2009 Dec; 5(7):652-7. PubMed ID: 19482531
[TBL] [Abstract][Full Text] [Related]
12. Periorbital infections after Dermabond closure of traumatic lacerations in three children.
Yeilding RH; O'Day DM; Li C; Alexander PT; Mawn LA
J AAPOS; 2012 Apr; 16(2):168-72. PubMed ID: 22525174
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
14. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
[TBL] [Abstract][Full Text] [Related]
15. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation.
Katoulis AC; Kanelleas A; Zambacos G; Panayiotides I; Stavrianeas NG
Dermatology; 2010 Aug; 221(1):9-12. PubMed ID: 20484878
[TBL] [Abstract][Full Text] [Related]
16. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
Popa C; Barrera P; Joosten LA; van Riel PL; Kullberg BJ; van der Meer JW; Netea MG
Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
[TBL] [Abstract][Full Text] [Related]
17. Tuberculous peritonitis after treatment with adalimumab.
Antolín J; Azahara M; Hernández C; Blanco M; Mao L; Cigüenza R
Scand J Infect Dis; 2008; 40(8):677-8. PubMed ID: 18979608
[TBL] [Abstract][Full Text] [Related]
18. Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung.
Weinblatt ME; Abbott GF; Koreishi AF
N Engl J Med; 2009 Apr; 360(17):1770-9. PubMed ID: 19387019
[No Abstract] [Full Text] [Related]
19. [Phlegmonous gastritis in a 44-year-old woman on immunosuppressive therapy].
Scheppach W; Illert B; Zettl A; Kneitz C; Scheurlen M
Dtsch Med Wochenschr; 2007 Jul; 132(30):1567-70. PubMed ID: 17628840
[TBL] [Abstract][Full Text] [Related]
20. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
Danko JR; Gilliland WR; Miller RS; Decker CF
Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
